News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CoLucid Pharmaceuticals, Inc. Names Linda Hogan VP of Business Development


10/28/2008 7:54:36 AM

INDIANAPOLIS, Oct. 28 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced today that it has appointed Linda Hogan as Vice President of Business Development. In this position, Hogan will apply more than 25 years of experience in the pharmaceutical and biopharmaceutical industries to drive CoLucid's business development strategies. She will lead partnering initiatives and transactions for the company's rapidly advancing pipeline of compounds for the treatment of central nervous system (CNS) disorders.

Hogan continues to serve as an Executive in Residence at Care Capital, LLC where she assists with the sourcing and evaluation of potential investment opportunities, including the formation of new companies, and provides business development support to portfolio companies. She previously served as Vice President of Business Development with Clearview Projects, Inc. and was Vice President of Business Development at Aventis. Hogan received an MBA from Rockhurst College and an MS in Hospital Pharmacy at the University of Kansas School of Pharmacy.

The company also announced that Nadia Rupniak has been promoted to Vice President of Research and Development, where she will lead the advancement of the company's late-stage and preclinical therapeutic candidates.

Rupniak has more than 20 years of experience in the pharmaceutical industry, including more than two years with CoLucid. She previously held positions at Merck and at Dynogen Pharmaceuticals, Inc, where she served as the head of technology transfer.

"We are building and adding to our team to support the continued advancement of COL-144 for the acute treatment of migraine and our other drug candidates," said James White, CEO of CoLucid Pharmaceuticals. "We congratulate Nadia Rupniak on her promotion, which reflects the important contributions she has made in helping CoLucid meet our clinical and research objectives, and we are very pleased to bring Linda Hogan on board. Linda is a skilled and accomplished business development professional who is able to draw on a breadth of experience at Care Capital and Clearview to help advance CoLucid's partnering initiatives."

"I look forward to working with CoLucid to help identify key business targets and to set the future direction of CoLucid's product development and partnering strategies," said Hogan. "I am very excited about the market and partnering potential for the company's pipeline of innovative CNS product candidates."

CoLucid Pharmaceuticals recently announced positive results from its Phase II clinical study of its lead compound, COL-144, in the treatment of acute migraine. Findings from the study demonstrated that COL-144 is effective in relieving migraine headaches and is well tolerated.

COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. COL-144 selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway. In addition to COL-144, CoLucid's pipeline includes a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. COL-204, the lead compound in the conjugated stigmine program, is expected to enter clinical development in 2009 for wake promotion.

About CoLucid Pharmaceuticals, Inc.

CoLucid Pharmaceuticals was founded in December 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for central nervous system (CNS) disorders. The company's pipeline includes COL-144, a novel treatment for migraine headache, and a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of sleep/wake disorders, chronic pain, Alzheimer's disease and psychiatric disorders. For more information, please visit CoLucid at www.colucid.com.

CONTACT: Megan Lavine of Porter Novelli Life Sciences, +1-619-849-5388,
mlavine@pnlifesciences.com, for CoLucid Pharmaceuticals, Inc.

Web site: http://www.colucid.com/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES